|
Pearce, C Leigh; Van Den Berg, David J; Makridakis, Nick et al. (2008) No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned. Hum Mol Genet 17:2456-61
|
|
Novelli, Giuseppe; Margiotti, Katia; Chiocca, Anna Maria et al. (2004) Pharmacogenetics of human androgens and prostate cancer--an update. Pharmacogenomics 5:283-94
|
|
Mehrian-Shai, Ruty; Reichardt, Juergen K V (2004) A renaissance of ""biochemical genetics""? SNPs, haplotypes, function, and complex diseases. Mol Genet Metab 83:47-50
|
|
Makridakis, Nick M; Reichardt, Juergen K V (2004) Molecular epidemiology of androgen-metabolic loci in prostate cancer: predisposition and progression. J Urol 171:S25-8; discussion S28-9
|
|
Allen, Naomi E; Reichardt, Juergen K V; Nguyen, Hannah et al. (2003) Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men. Cancer Epidemiol Biomarkers Prev 12:578-81
|
|
Pearce, Celeste L; Makridakis, Nick M; Ross, Ronald K et al. (2002) Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study. Cancer Epidemiol Biomarkers Prev 11:417-8
|
|
Hsing, A W; Chen, C; Chokkalingam, A P et al. (2001) Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 10:1077-82
|
|
Makridakis, N M; Reichardt, J K (2001) Molecular epidemiology of hormone-metabolic loci in prostate cancer. Epidemiol Rev 23:24-9
|
|
Makridakis, N M; Reichardt, J K (2001) Multiplex automated primer extension analysis: simultaneous genotyping of several polymorphisms. Biotechniques 31:1374-80
|
|
Novelli, G; Margiotti, K; Sangiuolo, F et al. (2001) Pharmacogenetics of human androgens and prostatic diseases. Pharmacogenomics 2:65-72
|
Showing the most recent 10 out of 19 publications
